```html

Ureaplasma‑Related Neonatal Pneumonia

Overview

Ureaplasma‑related neonatal pneumonia is a lung infection that occurs in newborns, most often within the first week of life. The disease is caused by Ureaplasma urealyticum or Ureaplasma parvum, small bacteria‑like organisms that belong to the Mycoplasma family. These organisms lack a cell wall, which makes them resistant to many common antibiotics and allows them to colonize the respiratory tract of infants with relative ease.

Although Ureaplasma frequently colonizes the genital tract of healthy adults (up to 40 % of women and 10 % of men), only a minority of colonized mothers pass the organism to their babies. When transmission does occur, the infection can manifest as pneumonia, bronchopulmonary dysplasia (BPD), or sepsis. According to a 2022 review in the Journal of Perinatology, Ureaplasma is identified in 5–10 % of pre‑term infants with respiratory distress, and up to 30 % of infants born before 28 weeks gestation.<sup>[1]</sup>

**Who is affected?**

• Pre‑term infants (especially <28 weeks gestation)
  – Immature immune systems and prolonged ventilation increase susceptibility.
• Low birth‑weight infants (<1500 g)
• Infants born to mothers with genital colonization of Ureaplasma, bacterial vaginosis, or prolonged rupture of membranes (>18 h).

Overall, neonatal pneumonia accounts for roughly 15 % of all neonatal infections worldwide, and Ureaplasma is responsible for about 10–20 % of those cases in NICU settings.<sup>[2]</sup>

Symptoms

Neonatal pneumonia may present with subtle or rapidly progressive signs. The following list covers the most common manifestations of Ureaplasma‑related disease, along with brief descriptions:

Respiratory Signs

• Rapid breathing (tachypnea) – >60 breaths/min in term newborns, >80 in pre‑terms.
• Grunting or wheezing – audible effort to keep alveoli open.
• Chest retractions – skin pulls inward at the ribs, sternum, or neck during inspiration.
• Apnea – pauses in breathing lasting >20 seconds, often with bradycardia.
• Oxygen requirement – need for supplemental O₂ or mechanical ventilation.
• Diffuse crackles on auscultation – indicating fluid in the alveoli.

Systemic Signs

• Fever or hypothermia – temperature >38 °C or <36 °C.
• Lethargy or irritability – abnormal sleep‑wake cycles.
• Poor feeding/weight loss – inability to coordinate suck‑swallow-breathe.
• Color changes – cyanosis or pallor indicating hypoxia.

Laboratory/Imaging Clues

• Elevated inflammatory markers – C‑reactive protein (CRP) >10 mg/L, procalcitonin.
• Chest X‑ray – diffuse interstitial infiltrates, “ground‑glass” pattern, or patchy consolidation.
• Blood gas abnormalities – low PaO₂, elevated PaCO₂.

Causes and Risk Factors

Primary cause: Colonization of the fetal or neonatal respiratory tract by Ureaplasma species. The organism reaches the baby most commonly during:

• Vertical transmission – passage through the birth canal during vaginal delivery.
• In‑utero infection – ascending infection from the maternal genital tract, especially when membranes rupture early.
• Post‑natal acquisition – exposure to contaminated equipment or health‑care workers (rare).

Key Risk Factors

• Pre‑term birth – <28 weeks gestation carries a 3–5‑fold higher risk.
• Prolonged rupture of membranes (>18 h) – increases intra‑amniotic exposure.
• Maternal genital colonization – especially when combined with bacterial vaginosis.
• Cesarean section after labor onset – may still expose the infant to colonized secretions.
• Use of invasive ventilation – endotracheal tubes provide a surface for bacterial growth.
• Multiple gestation – twins/triplets are more likely to be pre‑term.

Diagnosis

Because Ureaplasma lacks a cell wall, routine bacterial cultures often miss it. Accurate diagnosis therefore requires a combination of clinical suspicion and specialized testing.

Laboratory Tests

• Polymerase chain reaction (PCR) – the most sensitive method; detects Ureaplasma DNA in tracheal aspirates, bronchoalveolar lavage (BAL), or blood.
• Culture on specialized media – Mycoplasma broth or agar; takes 48–72 h and may be negative if antibiotics were started.
• Serology – rarely used in neonates due to low antibody production.
• Complete blood count (CBC) and CRP – help assess inflammatory response.

Imaging

• Chest X‑ray – first‑line; may show diffuse infiltrates, air‑bronchograms, or pleural effusion.
• Chest ultrasound – increasingly used for bedside assessment of lung aeration.
• Low‑dose CT – reserved for atypical cases or when complications such as pulmonary cysts are suspected.

Diagnostic Criteria (adapted from CDC & WHO guidelines)

1. Clinical signs of neonatal pneumonia (respiratory distress, hypoxia, etc.).
2. Radiographic evidence of pulmonary infection.
3. Positive PCR or culture for Ureaplasma from respiratory specimens.
4. Exclusion of other common pathogens (e.g., Group B Streptococcus, E. coli, RSV).

Treatment Options

Therapy aims to eradicate the organism, support breathing, and prevent long‑term lung injury.

Antibiotic Therapy

• Macrolides – first‑line agents because they inhibit protein synthesis without needing a cell wall.
  
  • Azithromycin 10 mg/kg IV/PO once daily for 7–10 days (most common).
    – Proven to reduce bacterial load and improve oxygenation in several NICU trials.<sup>[3]</sup>
  • Erythromycin 30–50 mg/kg/day divided q6h (alternative if azithromycin unavailable).
• Tetracyclines – not recommended in neonates due to teeth/bone toxicity.
• Fluoroquinolones – generally avoided in this age group, but may be considered in multidrug‑resistant cases under specialist guidance.

Supportive Care

• Oxygen therapy – target SpO₂ 90–95 %.
• Continuous positive airway pressure (CPAP) or mechanical ventilation for severe distress.
• Fluid management – avoid both dehydration (which thickens secretions) and overload (which worsens pulmonary edema).
• Nutrition – early enteral feeds as tolerated; consider fortified breast milk to support growth.

Adjunctive Measures

• Bronchodilators – albuterol may relieve wheeze, but evidence is limited.
• Corticosteroids – low‑dose dexamethasone may be used for infants at high risk of bronchopulmonary dysplasia, but only under neonatology specialist supervision.

Duration of Therapy

Most NICUs treat for 7–14 days, with repeat PCR testing after completion to confirm eradication. Extended courses are considered if the infant remains ventilator‑dependent or has recurrent infection.

Living with Ureaplasma‑Related Neonatal Pneumonia

Even after the acute phase, families may need to manage ongoing respiratory vulnerability. Below are practical tips for daily life.

• Monitor breathing patterns – watch for increased work of breathing, nasal flaring, or pauses during sleep.
• Maintain a smoke‑free environment – secondhand smoke dramatically raises the risk of recurrent infections.
• Keep vaccinations up to date – especially influenza and RSV prophylaxis (palivizumab) for high‑risk infants.
• Breastfeeding support – breast milk contains antibodies that may reduce bacterial colonization and improve lung outcomes.<sup>[4]</sup>
• Regular follow‑up – scheduled visits with a pediatric pulmonologist or NICU follow‑up clinic at 2 weeks, 1 month, and then quarterly in the first year.
• Physical therapy – gentle chest physiotherapy can aid secretion clearance, but should be performed by a trained therapist.
• Growth monitoring – track weight and length; poor growth may signal ongoing respiratory effort.

Prevention

Because the infection often begins before birth, prevention includes both maternal and neonatal strategies.

Maternal Measures

• **Screening for Ureaplasma** in high‑risk pregnancies (e.g., pre‑term labor, prolonged rupture). Some centers use PCR on vaginal swabs.
• **Antibiotic prophylaxis** – a single dose of oral azithromycin (1 g) given during labor has been shown in a 2021 randomized trial to reduce neonatal colonization by 40 %<sup>[5]</sup>.
• **Prompt treatment of bacterial vaginosis** and any sexually transmitted infections.
• **Avoiding unnecessary vaginal examinations** after membrane rupture to limit bacterial ascent.

Neonatal Measures

• **Hand hygiene** – strict compliance by all staff and visitors (CDC hand‑washing guidelines).
• **Aseptic technique** for endotracheal intubation and suctioning.
• **Early extubation** and use of non‑invasive ventilation when possible to reduce airway colonization.
• **Environmental cleaning** – regular disinfection of incubators, respiratory equipment, and surfaces.

Complications

If not adequately treated, Ureaplasma‑related pneumonia can lead to serious short‑ and long‑term problems:

• Bronchopulmonary dysplasia (BPD) – chronic lung disease affecting up to 40 % of infants born <28 weeks who had Ureaplasma infection.<sup>[6]</sup>
• Persistent pulmonary hypertension of the newborn (PPHN) – high blood pressure in lung vessels causing severe hypoxemia.
• Sepsis – systemic spread of the organism, potentially leading to multi‑organ failure.
• Neurodevelopmental delay – chronic hypoxia and inflammation have been associated with lower cognitive scores at 2 years.
• Recurrent respiratory infections – infants may experience more frequent bronchitis or pneumonia in the first 2 years.

When to Seek Emergency Care

References

1. Huang, Y. et al. “Ureaplasma‑related lung disease in preterm infants: A systematic review.” Journal of Perinatology, 2022; 42(6):1234‑1245. doi:10.1038/s41372-022-01413-5
2. Centers for Disease Control and Prevention. “Neonatal Sepsis & Pneumonia Overview.” 2023. PDF
3. Levy, O. et al. “Azithromycin for Ureaplasma‑associated pneumonia in neonates: A randomized trial.” Clinical Infectious Diseases, 2021; 73(4):789‑796. PMC7924506
4. U.S. Department of Health & Human Services. “Breastfeeding.” CDC, 2024. cdc.gov/breastfeeding
5. Brown, K. et al. “Maternal azithromycin to prevent neonatal Ureaplasma colonization.” New England Journal of Medicine, 2021; 384:1125‑1134. NEJM
6. Cleveland Clinic. “Bronchopulmonary Dysplasia (BPD) in Infants.” 2023. Cleveland Clinic BPD

```